Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection

Affiliations

¹ Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA. Khanna.Sahil@mayo.edu.
² University of Kansas School of Medicine-Wichita, Wichita, KS, USA.
³ University of Victoria, Victoria, BC, Canada.
⁴ Kaiser Permanente Springfield Medical Center, Springfield, VA, USA.
⁵ University of Calgary, Calgary, AB, Canada.
⁶ Arkansas Gastroenterology, North Little Rock, AR, USA.
⁷ Louisiana Research Center, Shreveport, LA, USA.
⁸ Ochsner Clinic, New Orleans, LA, USA.
⁹ University of Florida, Gainesville, FL, USA.
¹⁰ Berry Consultants, LLC, Austin, TX, USA.
¹¹ Formerly of Rebiotix, Inc, Roseville, MN, USA.
¹² Rebiotix, Inc, Roseville, MN, USA.
¹³ Yale School of Medicine, New Haven, CT, USA.
¹⁴ PACT Gastroenterology Center, Hamden, CT, USA.

Published Erratum

Sahil Khanna et al. Drugs. 2022 Oct.

. 2022 Oct;82(15):1539.

doi: 10.1007/s40265-022-01805-0.

¹ Gastroenterology and Hepatology, Mayo Clinic, 200 1st Street SW, Rochester, MN, 55905, USA. Khanna.Sahil@mayo.edu.
² University of Kansas School of Medicine-Wichita, Wichita, KS, USA.
³ University of Victoria, Victoria, BC, Canada.
⁴ Kaiser Permanente Springfield Medical Center, Springfield, VA, USA.
⁵ University of Calgary, Calgary, AB, Canada.
⁶ Arkansas Gastroenterology, North Little Rock, AR, USA.
⁷ Louisiana Research Center, Shreveport, LA, USA.
⁸ Ochsner Clinic, New Orleans, LA, USA.
⁹ University of Florida, Gainesville, FL, USA.
¹⁰ Berry Consultants, LLC, Austin, TX, USA.
¹¹ Formerly of Rebiotix, Inc, Roseville, MN, USA.
¹² Rebiotix, Inc, Roseville, MN, USA.
¹³ Yale School of Medicine, New Haven, CT, USA.
¹⁴ PACT Gastroenterology Center, Hamden, CT, USA.

No abstract available

Erratum for

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, Aguilar H, Garcia-Diaz J, Wang GP, Berry SM, Marion J, Su X, Braun T, Bancke L, Feuerstadt P. Khanna S, et al. Drugs. 2022 Oct;82(15):1527-1538. doi: 10.1007/s40265-022-01797-x. Epub 2022 Oct 26. Drugs. 2022. PMID: 36287379 Free PMC article. Clinical Trial.